Caris Life Sciences, Inc. (CAI) Revenue (2024 - 2026)

Caris Life Sciences (CAI) has reported Revenue for 3 consecutive years, with $216.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue rose 78.78% year-over-year to $216.2 million; the TTM figure through Mar 2026 stood at $907.3 million (up 100.51% YoY), while the FY2025 annual figure was $812.0 million, up 96.97% from the prior year.
• Revenue came in at $216.2 million for Q1 2026 at Caris Life Sciences, down from $292.9 million in the prior quarter.
• The five-year high for Revenue was $292.9 million in Q4 2025, with the low at $100.0 million in Q2 2024.
• Average Revenue over 3 years is $170.0 million, with a median of $155.7 million recorded in 2024.
• Across the five-year window, Revenue soared 125.44% in 2025 and jumped 78.78% in 2026, its largest moves.
• Year by year, Revenue stood at $129.9 million in 2024, then surged by 125.44% to $292.9 million in 2025, then retreated by 26.19% to $216.2 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $216.2 million, $292.9 million, and $216.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.